Insider Selling: Pharvaris (NASDAQ:PHVS) Insider Sells $1,149,000.00 in Stock

Pharvaris N.V. (NASDAQ:PHVS) insider Anne Lesage sold 30,000 shares of the stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $38.30, for a total value of $1,149,000.00. Following the transaction, the insider owned 56,450 shares in the company, valued at $2,162,035. This trade represents a 34.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Anne Lesage also recently made the following trade(s):

• On Tuesday, June 30th, Anne Lesage sold 30,703 shares of Pharvaris stock. The stock was sold at an average price of $35.49, for a total value of $1,089,649.47.
• On Tuesday, June 30th, Anne Lesage sold 27,872 shares of Pharvaris stock. The shares were sold at an average price of $35.48, for a total value of $988,898.56.
• On Monday, June 29th, Anne Lesage sold 6,997 shares of Pharvaris stock. The shares were sold at an average price of $35.05, for a total transaction of $245,244.85.
• On Monday, June 29th, Anne Lesage sold 10,600 shares of Pharvaris stock. The stock was sold at an average price of $35.07, for a total transaction of $371,742.00.

Pharvaris Price Performance

Shares of PHVS stock opened at $37.55 on Thursday. The firm’s 50-day simple moving average is $35.31 and its 200-day simple moving average is $31.63. Pharvaris N.V. has a 1-year low of $20.65 and a 1-year high of $43.25. The firm has a market cap of $2.46 billion, a P/E ratio of -12.31 and a beta of -2.33.

Pharvaris (NASDAQ:PHVS) last released its earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). Analysts expect that Pharvaris N.V. will post -3.12 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently commented on PHVS. UBS Group set a $79.00 price objective on Pharvaris in a report on Wednesday, September 9th. Leerink Partners lifted their target price on Pharvaris from $50.00 to $65.00 and gave the company an “outperform” rating in a report on Wednesday, September 9th. HC Wainwright reissued a “buy” rating and set a $60.00 price target on shares of Pharvaris in a research report on Tuesday, September 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Pharvaris in a research note on Friday, July 17th. Finally, Citizens Jmp raised their price objective on Pharvaris from $75.00 to $79.00 and gave the stock a “market outperform” rating in a report on Wednesday, September 9th. Thirteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $59.87.

Institutional Investors Weigh In On Pharvaris

Large investors have recently made changes to their positions in the business. venBio Partners LLC acquired a new position in shares of Pharvaris during the 2nd quarter valued at $160,569,809. Wellington Management Group LLP increased its holdings in Pharvaris by 12.9% in the 2nd quarter. Wellington Management Group LLP now owns 2,392,934 shares of the company’s stock valued at $82,748,000 after purchasing an additional 274,034 shares in the last quarter. Commodore Capital LP increased its holdings in Pharvaris by 1.6% in the 1st quarter. Commodore Capital LP now owns 1,918,970 shares of the company’s stock valued at $54,211,000 after purchasing an additional 29,525 shares in the last quarter. 5AM Venture Management LLC purchased a new position in Pharvaris in the second quarter valued at about $27,581,008. Finally, Seven Fleet Capital Management LP raised its position in Pharvaris by 144.6% in the second quarter. Seven Fleet Capital Management LP now owns 774,501 shares of the company’s stock valued at $26,782,000 after purchasing an additional 457,804 shares during the period.

Pharvaris News Roundup

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Pharvaris’ phase III data showed that once-daily extended-release deucrictibant reduced hereditary angioedema attacks by 83%. The result strengthens the case for the company’s lead drug and supports planned regulatory submissions in 2027. PHVS Stock Rises 10% in a Month: What Is Driving the Rally?
• Positive Sentiment: Analyst expectations remain favorable. The reported consensus price target rose 20.08% to $59.77, while recent targets include $62 from RBC and $65 from Wells Fargo and Leerink Partners. The broader analyst consensus is “Moderate Buy.” Pharvaris Consensus Price Target Raised
• Positive Sentiment: Recent institutional activity has been supportive, including a new BlackRock position and larger holdings from Alyeska Investment Group and Seven Fleet Capital, suggesting increased professional-investor interest.
• Neutral Sentiment: Pharvaris presented at the Morgan Stanley 24th Annual Global Healthcare Conference. The event provided management with an opportunity to discuss deucrictibant and its regulatory strategy, but the supplied transcript does not identify a separate new announcement. Pharvaris Morgan Stanley Conference Transcript
• Negative Sentiment: Insider selling is weighing on sentiment. Insider Wim Souverijns sold 26,090 shares for approximately $1.02 million across September 14–15, while CEO Berndt Modig sold 2,291 shares worth about $90,265. President Peng Lu also sold 15,000 shares for roughly $602,000 to cover tax withholding related to vested equity awards. Anne Lesage separately sold 30,000 shares for approximately $1.15 million. Although some sales were tax-related and insiders retain significant holdings, the volume of selling can raise concerns about near-term supply and insider confidence. Pharvaris Insider Selling

About Pharvaris

Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.

Pharvaris’ lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.